Новости за 05.02.2019

The scientists, it would seem, have finally got on to something really big, something which has baffled philosophers for centuries. Whereas we have been brought up on the old saw that money won’t buy happiness, a study conducted by the US Public Health Service would seem to indicate the contrary. The findings were substantiated by a survey of a random sample of some 1,400 Puerto Ricans who were interviewed on the island during a six-month period in 1963-1964. The sample was validated by questioning 114 outpatients of a psychiatric hospital... Читать дальше...

This before-after study examines the association between value-based incentive programs that link financial rewards and penalties to hospital performance on quality indicators and catheter-associated urinary tract infection outcomes in intensive care units (ICUs).

To the Editor We agree with Dr Schenker and colleagues that palliative care teams are well positioned to support patients with advanced illnesses and concurrent nonmedical opioid use because of their clinical expertise in symptom management, interdisciplinary nature, and emphasis on psychosocial aspects of care. We have 2 comments.

To the Editor Dr Gupta and colleagues summarized 4 of the major new recommendations in the updated guidelines from the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) on the diagnosis and treatment of Clostridium difficile infection (CDI). We would like to clarify the recommendations for treatment of recurrent CDI and emphasize the need for better quality of evidence to guide future recommendations in this situation.

To the Editor In their Editorial on physician burnout, Drs Schwenk and Gold missed an opportunity to enhance efforts to address the burnout problem. They called for increased research into burnout to better define its scope and characteristics.

In Reply In response to our Viewpoint highlighting educational, research, and policy issues raised by use of palliative care earlier in the disease course in the context of the opioid epidemic, Dr Hui and colleagues note that palliative care specialists have long recognized opioid use disorders as a concern among patients with serious illness and are well trained to manage opioid misuse and addiction.

In Reply We believe that the recent IDSA/SHEA guidelines on diagnosis and treatment of CDI are a significant update and provide treating clinicians with tools to better diagnose and manage CDI. There have been some important changes from earlier guidelines. We agree that the recommendations for treatment of recurrent CDI with either a tapered and pulsed vancomycin regimen, a standard fidaxomicin regimen, or a vancomycin regimen are based on weak data, as this particular question has not been studied systematically.

In Reply As we said in our Editorial, we agree completely with Dr Levine that something important and serious is affecting the work satisfaction of physicians. Whatever it is requires attention and solution. However, burnout is so heterogeneous in its makeup and assessment that any solutions also are likely to be heterogeneous.

This Medical Letter review summarizes doses and formulations of Imvexxy, an estradiol softgel vaginal insert that was recently approved to treat moderate to severe dyspareunia due to vulvovaginal atrophy in postmenopausal women.

This randomized clinical trial compares the effect of a magnetic resonance imaging (MRI)–guided vs a conventional clinical treat-to-remission-target strategy on improving disease activity scores and radiographic progression in patients with rheumatoid arthritis (RA) in clinical remission.

This population-based cohort study compares standardized reading and mathematics test scores of Danish public schoolchildren with vs without type 1 diabetes to assess the association between diabetes and school performance.

This pragmatic randomized trial compares the effects of EEG-guided anesthetic administration vs usual anesthetic care on incident postoperative delirium among older adults undergoing major surgery.

This JAMA Patient Page describes genital warts and their cause, risk factors, treatment, and prevention.

The body is the personwho we cannot leave—made bit by bitwe hope with tenderness,vulnerable in the womband after the first breath,since an egg accepted a spermwhether in a coral showeror a dance of whales,whether on a mountain or in tidal poolsor in the warm shell of the placentawhere compassion holds the cord that feedsthrough the swimming monthsand the growing folds,most still unknown—Let us have luckand breathe.

In this narrative medicine essay, a researcher diagnosed with degenerative retinal disease discusses the challenge of being a scientist with a disability and describes how she worked through institutional barriers, depression, and fear with help from peers and mentors to bring insights and energy to a career focusing on vision loss in patients.

This Rational Clinical Examination systematic review characterizes the accuracy of clinical features and bedside tests for predicting difficult endotracheal intubation.

Paris-based Sanofi announced positive results from its pivotal Phase III trial of isatuximab in patients with relapsed/refractory multiple myeloma.

Catalyst won approval in 2018 for the LEMS treatment and set the price of the drug at $375,000 for the rare disease.

According to a real estate analysis, the per-square-foot costs in Kendall Square increased $18 in 2018.

Eli Lilly and Co. has licensed 2G UNic technology from Leiden, the Netherlands-based ProteoNic Biotechnology BV. The tech is used to improve recombinant protein production. No financial details were disclosed.

Gilead Sciences reported earnings per share profits for the fourth quarter of $1.44 per share, below analysts’ expectations of $1.70.

IDEA Pharma recently published its “Pharmaceutical Innovation Index 2018.” This report ranks biopharma companies on their ability to bring products from Phase I/II to market and then successfully commercialize them. They used a variety of sources, including company websites, third-party instituti...

Genentech, a Roche company, is flexing its litigation muscle this week. The South San Francisco-based company has filed 18 lawsuits over the past few weeks to block competitors from selling a generic version of a treatment for idiopathic pulmonary fibrosis, a fatal lung-scarring disease.

Nokia and Zain KSA have launched a Massive MIMO trial in the Saudi Arabian city of Jeddah, which aims to deliver download speeds of up to 700Mbps. The trial uses spectrum in the 2.6GHz range over Zain's LTE network and will utilise Nokia's 5G ready AirScale Massive MIMO antenna for 4…

read more on TotalTele.com »

Indian state-owned telecoms operator BSNL has launched its fibre to the home (FTTH) broadband service, which will bring superfast connectivity to millions of people across the country. BSNL will offer a number of speed tariffs…

read more on TotalTele.com »